MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 15, 2008; DOI: 10.1124/mol.107.044115


0026-895X/08/7402-454-465$20.00
Mol Pharmacol 74:454-465, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.044115v1
74/2/454    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Blanke, M. L.
Right arrow Articles by VanDongen, A. M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blanke, M. L.
Right arrow Articles by VanDongen, A. M. J.

The NR1 M3 Domain Mediates Allosteric Coupling in the N-Methyl-D-aspartate Receptor

Marie L. Blanke, and Antonius M. J. VanDongen

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina (M.L.B., A.M.J.V.); and Duke-NUS Graduate Medical School, Singapore, Singapore (A.M.J.V.)

N-Methyl-D-aspartate (NMDA) receptors play a critical role in both development of the central nervous system and adult neuroplasticity. However, although the NMDA receptor presents a valuable therapeutic target, the relationship between its structure and functional properties has yet to be fully elucidated. To further explore the mechanism of receptor activation, we characterized two gain-of-function mutations within the NR1 M3 segment, a transmembrane domain proposed to couple ligand binding and channel opening. Both mutants (A7Q and A7Y) displayed significant glycine-independent currents, indicating that their M3 domains may preferentially adopt a more activated conformation. Substituted cysteine modification experiments revealed that the glycine binding clefts of both A7Q and A7Y are inaccessible to modifying reagents and resistant to competitive antagonism. These data suggest that perturbation of M3 can stabilize the ligand binding domain in a closed cleft conformation, even in the absence of agonist. Both mutants also displayed significant glutamate-independent current and insensitivity to glutamate-site antagonism, indicating partial activation by either glycine or glutamate alone. Furthermore, A7Q and A7Y increased accessibility of the NR2 M3 domain, providing evidence for intersubunit coupling at the transmembrane level and suggesting that these NR1 mutations dominate the properties of the intact heteromeric receptor. The equivalent mutations in NR2 did not exhibit comparable phenotypes, indicating that the NR1 and NR2 M3 domains may play different functional roles. In summary, our data demonstrate that the NR1 M3 segment is functionally coupled to key structural domains in both the NR1 and NR2 subunits.


Received December 4, 2007; accepted April 28, 2008

Address correspondence to: Dr. Antonius M. J. VanDongen, Duke-NUS Graduate Medical School, 2 Jalan Bukit Merah, Singapore 169547, Singapore. E-mail vando005{at}mc.duke.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics